ÂÜÀòÂÒÂ×

Valerie is Co-Founder and Chief Scientific Officer of Eliem Therapeutics. Valerie has more than 20 years’ experience in the pharmaceutical industry, with positions of increasing responsibility at Novartis, GSK, Convergence and Biogen. Prior to joining Eliem, Valerie was a founding venture partner at Bridge Valley Ventures. She co-founded Convergence Pharmaceuticals, where she established and led the Biology and Translational Medicine team, and she was instrumental in the sale of Convergence to Biogen for $675M in 2015. Valerie subsequently joined Biogen in a senior leadership role. She has worked extensively in the field of drug development for pain and across a number of other therapeutic areas including neurology, psychiatry, gastrointestinal disorders and sensory biology. Valerie trained as an electrophysiologist and completed her doctorate at the University of Bordeaux.